|
|
|
08.07.26 - 14:03
|
ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD) (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The granted claims cover methods of treating non-aggressive symptoms of borderline personality disorder (BPD) using LSD1 inhibitors, including vafidemstat, complementing Oryzon's patent portfolio covering the treatment of aggression....
|
|
|
|
|
01.07.26 - 15:12
|
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced the successful completion of a €12 million gross capital increase through the issuance of 4,444,445 new ordinary shares, at a subscription price of €2.70 per share. This pricing represents a 14.15% discount to the five-day volume-weighted average price (VWAP), which was €3.1449, and a 12.68% discount to the June 30 closing price of €3.092 per share. The offering was structured as a capital increase without the issuance of warrants. Singular Bank acted as placement agent in Spain, and All-Invest acted as placement agent in the EU and the UK. Banco Sabadell, S.A. acted as Agent Bank and Technical Pre-Financing Entity for the capital increase, while Gómez-Acebo & Pombo Abogados, S.L.P. acted as legal counsel to the Company....
|
|
|
|
|
|
|
|
|
15.06.26 - 14:03
|
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. (GlobeNewswire EN)
|
|
|
BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia....
|
|
|
|
|
|
|
10.06.26 - 18:30
|
Cursor kündigt Ausbau der Niederlassung und des Teams in der EMEA-Region an, um der regionalen Nachfrage gerecht zu werden (Business Wire)
|
|
|
Der Hauptsitz in London wird diesen Sommer eröffnet und bis zum Jahresende auf rund 200 Mitarbeiter anwachsen, da die EMEA-Region für Cursor zur am schnellsten wachsenden Region wirdLONDON--(BUSINESS WIRE)--Cursor, die führende Multi-Modell-KI-Codierungsplattform, gab heute die Einrichtung spezieller Teams für die EMEA-Region bekannt. Die Expansion ist eine Reaktion auf die regionale Dynamik, da sich der Umsatz in der EMEA-Region in diesem Jahr im Quartalsvergleich verdreifacht hat.
Das Cursor-EMEA-Team wird einen schnell wachsenden Kundenstamm betreuen, zu dem British Airways, BP, Deliveroo, Nokia, Sanofi und viele andere führende Unternehmen in der Region gehören. Cursor rechnet damit, die Mitarbeiterzahl in der EMEA-Region bis zum Jahresende auf rund 200 Mitarbeiter zu erhöhen und stellt in den Bereichen Go-to-Market, Engineering, Customer Success und Operations ein.
„Wir freuen uns unglaublich darauf, Cursor offiziell in der gesamten EMEA-Region zu starten und unser Engagement für Kunden und...
|
|
|
09.06.26 - 07:06
|
Cursor Announces EMEA Office and Team Expansion to Meet Regional Demand (Business Wire)
|
|
|
London headquarters will open this summer and grow to approximately 200 employees by year-end as EMEA becomes Cursor's fastest-growing regionLONDON--(BUSINESS WIRE)--Cursor, the leading multi-model AI coding platform, today announced the establishment of dedicated teams to serve the EMEA region. The expansion responds to regional momentum, with EMEA revenue tripling quarter over quarter this year.
The Cursor EMEA team will support a rapidly expanding customer base that includes British Airways, BP, Deliveroo, Nokia, Sanofi and many other leading enterprises across the region. Cursor expects to grow its EMEA headcount to approximately 200 employees by the end of the year, hiring across go-to-market, engineering, customer success and operations.
“We're incredibly excited to officially launch Cursor across EMEA and deepen our commitment to customers and partners throughout Europe. As the leading AI coding company, our goal is simple: be closer to the teams building the future and help enterprises acceler...
|
|
|
05.06.26 - 22:18
|
Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1 (PR Newswire)
|
|
|
The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C., June 5, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit detection organization powered and funded by the......
|
|
|
03.06.26 - 17:48
|
Börsenradio Schlussbericht, Mi., 03.06.2026: Hormus bremst DAX und Wall Street - Interviews live aus Dubai und digitaler Euro (BRN)
|
|
|
Die Straße von Hormus steht wieder im Mittelpunkt der Märkte. Brent steigt auf rund 100 USD, ein Plus von knapp 2 %. Der DAX fällt wieder unter die Marke von 25.000 Punkten. Kampfhandlungen im Nahen Osten stoppen auch die Rekordjagd an der Wall Street: Dow Jones, S&P 500 und Nasdaq starten leichter. Bitcoin fällt auf ein 2-Monats-Tief bei 65.000 USD, Gold rutscht unter 4.500 USD. Bei den Einzelwerten geht es um den möglichen SpaceX-Börsengang mit 135 USD je Aktie und einer Bewertung von 1,75 Bio. USD, um Bayer und die Glyphosat-Risiken, um Personalsorgen bei der Lufthansa, einen Kurssprung bei GameStop nach 14 % Umsatzplus und einem 2-Mrd.-USD-Rückkaufprogramm, starke Margen bei Inditex sowie Microsofts neuen Quantenchip mit dem Zieljahr 2029. Und zum Schluss die Börsenweisheit des Tages. Sie kommt von Philip Fisher: "Der Aktienmarkt ist voll von Menschen, die den Preis von allem kennen, aber den Wert von nichts." Nächster Marktbericht hören Sie am kommenden Montag....
|
|
|
|
|
|
|
14.05.26 - 16:51
|
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026 (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended March 31, 2026, and provided a corporate update on recent developments....
|
|
|
|
|
|
|
13.05.26 - 14:03
|
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that updated positive clinical data from two Phase Ib clinical trials evaluating its selective LSD1 inhibitor iadademstat in acute myeloid leukemia (AML) will be presented in two poster sessions at the European Hematology Association (EHA) Annual Congress, taking place June 11-14, 2026 in Stockholm, Sweden.“We are encouraged by the updated findings from both the ALICE-2 and FRIDA trials, which continue to support the clinical activity and favorable safety profile of iadademstat-based combinations in AML,” said Carlos Buesa, Chief Executive Officer of Oryzon. “We look forward to presenting updated data at EHA 2026 from a larger patient cohort in the ALICE-2 study, likely representing approximately 75–80% of the planned enrollment, which we believe will provide a more mature assessment of b...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
